|
1
|
A new factor in the production and cure of macrocytic anaemias and its relation to other haemopoietic principles curative in pernicious anaemia.
|
Biochem J
|
1937
|
1.89
|
|
2
|
Carboplatin (Paraplatin; JM8) and etoposide (VP-16) as first-line combination therapy for small-cell lung cancer.
|
J Clin Oncol
|
1987
|
1.47
|
|
3
|
Carbon monoxide diffusing capacity is a poor predictor of clinically significant bleomycin lung. New Zealand Clinical Oncology Group.
|
J Clin Oncol
|
1990
|
1.39
|
|
4
|
Differences in expression of lupus nephritis in New Zealand mixed H-2z homozygous inbred strains of mice derived from New Zealand black and New Zealand white mice. Origins and initial characterization.
|
Lab Invest
|
1993
|
1.38
|
|
5
|
Adjuvant chemotherapy for non-metastatic osteosarcoma of the extremities in two New Zealand cancer centres.
|
Aust N Z J Med
|
1995
|
1.38
|
|
6
|
Phase II study of JM8, a new platinum analog, in advanced ovarian carcinoma.
|
Cancer Treat Rep
|
1983
|
1.32
|
|
7
|
Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent.
|
Br J Cancer
|
2003
|
1.15
|
|
8
|
A randomized comparison of single-agent doxorubicin and epirubicin as first-line cytotoxic therapy in advanced breast cancer.
|
J Clin Oncol
|
1991
|
0.99
|
|
9
|
Carboplatin: a very active new cisplatin analog in the treatment of small cell lung cancer.
|
Cancer Treat Rep
|
1985
|
0.93
|
|
10
|
Predictors of favorable outcome following naltrexone treatment.
|
Drug Alcohol Depend
|
1983
|
0.91
|
|
11
|
Risk factors for early hospital readmission after cardiac operations.
|
J Thorac Cardiovasc Surg
|
2001
|
0.91
|
|
12
|
Monoclonal antibody to native P39 protein from Borrelia burgdorferi.
|
J Clin Microbiol
|
1994
|
0.90
|
|
13
|
A comparison of the response of human lung carcinoma xenografts to vindesine and vincristine.
|
Br J Cancer
|
1982
|
0.90
|
|
14
|
Determination of citrinin in corn and barley.
|
J Assoc Off Anal Chem
|
1978
|
0.89
|
|
15
|
Phase I trial and pharmacokinetics of trimelamol (N2,N4,N6-trihydroxymethyl-N2,N4,N6-trimethylmelamine).
|
Cancer Res
|
1989
|
0.87
|
|
16
|
Inpatient alcohol treatment in a private healthcare setting: which patients benefit and at what cost?
|
Am J Addict
|
1999
|
0.87
|
|
17
|
Quality assurance for digital imaging.
|
J Digit Imaging
|
1997
|
0.85
|
|
18
|
Inpatient vs outpatient treatment for substance dependence revisited.
|
Psychiatr Q
|
1993
|
0.85
|
|
19
|
Phase I study of the cytotoxic agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide.
|
Cancer Chemother Pharmacol
|
1999
|
0.84
|
|
20
|
JMS, successor to cisplatin in advanced ovarian carcinoma?
|
Lancet
|
1983
|
0.84
|
|
21
|
Autologous bone marrow rescue is unnecessary after very-high-dose cyclophosphamide.
|
Lancet
|
1983
|
0.83
|
|
22
|
High-dose cyclophosphamide with autologous bone marrow rescue after conventional chemotherapy in the treatment of small cell lung carcinoma.
|
Cancer Chemother Pharmacol
|
1985
|
0.82
|
|
23
|
Plasma pharmacokinetics of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in a phase I trial.
|
Cancer Chemother Pharmacol
|
1999
|
0.82
|
|
24
|
Tamoxifen and life-threatening hypercalcaemia.
|
Lancet
|
1979
|
0.82
|
|
25
|
Normal tissue toxicity and antitumour experiments carried out in mice using high-dose cyclophosphamide.
|
Cancer Treat Rev
|
1983
|
0.81
|
|
26
|
Ductography is a useful technique in evaluation of abnormal nipple discharge.
|
Am Surg
|
1996
|
0.81
|
|
27
|
Reduction of carboplatin induced emesis by ondansetron.
|
Br J Cancer
|
1991
|
0.80
|
|
28
|
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
|
Eur J Cancer
|
1994
|
0.80
|
|
29
|
Metabolism of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide in cancer patients undergoing a phase I clinical trial.
|
Cancer Chemother Pharmacol
|
1999
|
0.80
|
|
30
|
High dose cyclophosphamide treatment of human oat cell xenografts in immune deprived mice.
|
Br J Cancer
|
1983
|
0.80
|
|
31
|
The use of antidepressants with methadone in depressed maintenance patients.
|
Ann N Y Acad Sci
|
1982
|
0.78
|
|
32
|
Carboplatin (JM8) as a single agent and in combination in the treatment of small cell lung cancer.
|
Cancer Treat Rev
|
1985
|
0.77
|
|
33
|
Prevention of acute deaths in mice after very high dose cyclophosphamide by divided dose schedule.
|
Br J Cancer
|
1984
|
0.77
|
|
34
|
Structure-activity-relationships of certain hallucinogenic substances based on brain levels.
|
Life Sci
|
1977
|
0.77
|
|
35
|
Incidence of personality disorders in cocaine vs. alcohol-dependent females.
|
NIDA Res Monogr
|
1990
|
0.76
|
|
36
|
Impulsivity and substance abusers: changes with treatment and recovery.
|
NIDA Res Monogr
|
1990
|
0.75
|
|
37
|
Palliation of biliary obstruction in patients with advanced breast cancer using endoscopic stents.
|
Br J Surg
|
1993
|
0.75
|
|
38
|
The Lancet, 311-314; A new factor in the production and cure of certain macrocytic anaemias.
|
Nutr Rev
|
1979
|
0.75
|
|
39
|
The effect of ethylenedinitrilotetraacetic acid (EDTA) on the reaction between the guinea-pig C5 convertase and guinea-pig C5.
|
Mol Immunol
|
1984
|
0.75
|
|
40
|
HCG--choosing the best assay to monitor gestational trophoblastic disease and other germ cell tumours.
|
N Z Med J
|
1993
|
0.75
|
|
41
|
Ondansetron reduces chemotherapy induced nausea and vomiting refractory to standard antiemetics.
|
N Z Med J
|
1992
|
0.75
|
|
42
|
Predictors of favorable outcome following naltrexone treatment.
|
NIDA Res Monogr
|
1983
|
0.75
|
|
43
|
High-dose cyclophosphamide (7 g/m2) with or without autologous bone marrow rescue after conventional chemotherapy in the treatment of patients with small cell lung cancer.
|
Cancer Treat Rev
|
1983
|
0.75
|
|
44
|
The natural history of outpatient alcohol and drug abuse treatment in a private healthcare setting.
|
Alcohol Clin Exp Res
|
1996
|
0.75
|
|
45
|
Guide to practical clinical psychopharmacology.
|
Pa Med
|
1979
|
0.75
|
|
46
|
Macromerine, normacromerine and bisnormacromerine: non-psychoactive methylated derivatives of norepinephrine.
|
Psychopharmacologia
|
1973
|
0.75
|
|
47
|
Vindesine as a single agent and in combination with adriamycin in the treatment of metastatic breast carcinoma.
|
Eur J Cancer
|
1980
|
0.75
|
|
48
|
"High"- and "low"-potency antipsychotic drugs.
|
Psychopharmacol Bull
|
1980
|
0.75
|
|
49
|
Metastasizing leiomyoma of the uterus.
|
Aust N Z J Obstet Gynaecol
|
1988
|
0.75
|
|
50
|
Physiological disposition of isoergine (from Argyreia nervosa (Burm. f.) Bojer Convolvulaceae) and its effect on the conditioned avoidance response in rats.
|
Psychopharmacologia
|
1972
|
0.75
|
|
51
|
HIV-risk behaviors among a middle class population: a preliminary investigation among adolescent vs. adult substance users.
|
NIDA Res Monogr
|
1990
|
0.75
|
|
52
|
Patient assessment of a combined medical and nursing preparation to cytotoxic chemotherapy.
|
Support Care Cancer
|
1993
|
0.75
|
|
53
|
Penetration of some O-and/or N-methylated norepinephrine derivatives through the rat blood brain barrier.
|
Res Commun Chem Pathol Pharmacol
|
1977
|
0.75
|
|
54
|
Treatment of mixed abusers in methadone maintenance: role of psychiatric factors.
|
Ann N Y Acad Sci
|
1982
|
0.75
|
|
55
|
Interaction of Zn2+ with guinea-pig C5 convertase and guinea-pig C5.
|
Mol Immunol
|
1984
|
0.75
|
|
56
|
beta-Hydroxylation as a possible detoxification mechanism: role in schizophrenia.
|
Biol Psychiatry
|
1977
|
0.75
|